(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
28 October 2021 (28.10.2021)

WIPO | PCT

(10) International Publication Number
WO 2021/214126 A1

(51) International Patent Classification:
A61K 47/68 (2017.01) *A61P 35/00* (2006.01)

(21) International Application Number:
PCT/EP2021/060352

(22) International Filing Date:
21 April 2021 (21.04.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
20382320.8 21 April 2020 (21.04.2020) EP

(71) Applicant: **PHARMA MAR, S.A.** [ES/ES]; Polígono Industrial La Mina Avda. de los Reyes, 1 Colmenar Viejo, 28770 Madrid (ES).

(72) Inventors: **LATORRE LOZANO, Alfonso**; c/o Pharma Mar, S.A. Polígono Industrial La Mina Avda. de los Reyes, 1 Colmenar Viejo, 28770 Madrid (ES). **MARTÍNEZ BARRASA, Valentín**; c/o Pharma Mar, S.A. Polígono Industrial La Mina Avda. de los Reyes, 1 Colmenar Viejo, 28770 Madrid (ES). **FRANCESCH SOLLOSO, Andrés M.**; c/o Pharma Mar, S.A. Polígono Industrial La Mina Avda. de los Reyes, 1 Colmenar Viejo, 28770 Madrid (ES). **CUEVAS MARCHANTE, María Del Carmen**; c/o Pharma Mar, S.A. Polígono Industrial La Mina Avda. de los Reyes, 1 Colmenar Viejo, 28770 Madrid (ES).


(74) Agent: **MARKS & CLERK LLP**; 62-68 Hills Road, Cambridge CB2 1LA (GB).


(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: DRUG ANTIBODY CONJUGATES

FIGURE 1





(I)

(57) Abstract: Drug conjugates having formula $[D\text{-}(X)_b\text{-}(AA)_w\text{-}(T)_g\text{-}(L)\text{-}]_n\text{-}Ab$ wherein: D is a drug moiety having the following formula (I) or a pharmaceutically acceptable salt, ester, solvate, tautomer or stereoisomer thereof, (I) wherein D is covalently attached via a hydroxy or amine group to $(X)_b$ if any, or $(AA)_w$ if any, or to $(T)_g$ if any, or (L); that are useful in the treatment of cancer.

[Continued on next page]

WO 2021/214126 A1

Published:
— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*